Lung Cancer Trial, Recruiting NCT06122077 Sponsor: Freenome Holdings Inc. Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06122077
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 50 years of age or older at the time of joining the trial (within 30 days of enrollment)
  • People who currently smoke or used to smoke, with a total smoking history of at least 20 pack-years (a measure of how much someone has smoked over their lifetime)
  • People who are able to understand and are willing to sign and date the required consent and privacy documents

Who may not be able to join:

  • People who are currently receiving any treatment for cancer, such as surgery, chemotherapy, biological therapy, immunotherapy, or radiation therapy
  • People who have been diagnosed with any cancer in the past 5 years (except for certain common skin cancers that are not melanoma)
  • People who have had an organ, tissue, or bone marrow transplant at any point
  • People who have already been screened for lung cancer or who have had a chest CT scan in the 12 months before joining the trial
  • People who are currently experiencing signs or symptoms that may be associated with lung cancer, such as coughing up blood or certain hormone- or pressure-related conditions (confirm with trial site)
  • People who have received a blood transfusion in the 30 days before joining the trial
  • People who are known to be pregnant
  • People who are currently participating in, or have previously participated in, another clinical study sponsored by Freenome
  • People who have taken part in another clinical research study involving an experimental medication in the 60 days before joining the trial
  • People who have any condition that the trial investigator believes makes joining the study inappropriate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Victoria Sumner, Freenome Holdings Inc.

Phone: 925-322-6486

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Freenome Holdings Inc.
Registry
ClinicalTrials.gov
Start date
28 November 2023
Est. completion
15 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sensitivity and specificity in detecting lung cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov